The GLP-1 track ushers in a new milestone with oral formulations: BRY Pharmaceutical's dual-target new drug reshaping the weight loss pathway

Log in to the Sina Finance app and search for 【disclosure of information】 to view more evaluation tiers

Against the backdrop of weight-loss drugs becoming a core track in the global pharmaceutical industry, the competitive logic for GLP-1-class drugs is changing. From the initial stage of validating “whether it works,” the industry is gradually moving into a new phase of “overall optimality in efficacy, safety, and adherence.”

After Borui Pharmaceutical (rights protection) disclosed Phase I clinical data for oral GLP-1/GIP dual-receptor agonist BGM0504 tablets, a technical path that balances depth of efficacy with the medication experience has started to become clear. As one of the few dual-target peptide oral formulations currently in the clinical stage, the outstanding safety and initial efficacy demonstrated by BGM0504 tablets offer new hope for overweight and obese patients worldwide.

Dual-target synergy enables a new oral weight-loss paradigm

From the global development path of weight-loss drugs, the industry is continuing to evolve along three main lines.

First, the route of administration is expanding from injections to oral dosing. Oral formulations mean broader coverage for more people and higher long-term adherence; this is a key step for weight-loss drugs to move from specialist treatment to chronic-disease management.

Second, the mechanism of action is shifting from single GLP-1 receptor agonism to multi-target synergy. The overlap of GLP-1 and pathways such as GIP not only delivers stronger weight-loss effects, but also enables systemic improvement across multiple dimensions such as blood sugar, blood lipids, and blood pressure, gradually giving weight-loss drugs metabolic comprehensive management attributes.

Third, small-molecule non-peptide routes are rapidly rising, attempting to provide alternatives through higher oral absorption efficiency and lower production costs. However, there are still certain challenges in receptor selectivity, duration of pharmacodynamic effects, and adverse-reaction control.

Against this backdrop of technological differentiation, oral dual-target peptide pathways are beginning to show unique advantages. On the one hand, peptide structures offer higher receptor selectivity and physiological compatibility; on the other hand, with advances in oral delivery technology, their pharmacodynamic performance is progressively approaching that of injections, while significantly improving the medication experience.

BGM0504 is positioned at this intersection. Its oral GLP-1/GIP dual-target design gives it, from the start, the dual attributes of “mechanism upgrade + administration route upgrade.”

Clinical data validates the value of dual-target synergy

Mechanistically, GLP-1 and GIP have an inherent synergistic relationship in metabolic regulation. GLP-1 mainly works by suppressing appetite, slowing gastric emptying, and reducing energy intake, while GIP plays a role in lipid metabolism and regulation of insulin sensitivity. When both are combined, weight loss shifts from single-pathway regulation to system-level metabolic remodeling. This mechanistic advantage has been preliminarily validated by clinical data.

According to the company announcement, in the Phase I study in China, after continuous dosing for 4 weeks, the body weight of each dosage group decreased from baseline by 1.04% to 5.56%; in the Phase I study in the United States, after dosing for 5 to 8 weeks, the weight-loss range further improved to 2.7% to 8.2%.

Worth noting is that this “continuous decline rather than a rapid peak” weight-loss curve is closer to the result of sustained modulation of metabolic pathways, rather than weight fluctuations caused by short-term stimulation. This also indirectly reflects the depth of dual-target synergy at the metabolic level.

By contrast, some non-peptide small-molecule routes still primarily rely on single-target mechanisms. Their in vivo exposure often shows characteristics of rapid peak and rapid decay, which is closer to pulse-like stimulation. Efficacy stability and the upper limit still need further validation.

Safety and PK differences form the core dividing line

In competition among oral GLP-1 drugs, differences in safety and adherence are, in essence, determined by pharmacokinetic characteristics.

Small-molecule drugs typically show a blood concentration curve characterized by “rapid absorption—rapid peak—rapid decay.” Under a daily dosing regimen, this leads to frequent fluctuations, which are more likely to cause gastrointestinal discomfort and are further amplified as the dosage is increased.

Peptide drugs, however, are different. Their metabolic pathway is closer to physiological processes. They usually have a longer half-life and more gradual blood concentration changes, which makes drug exposure more stable—thereby maintaining therapeutic effects while lowering the likelihood of adverse reactions.

This difference is directly reflected in the Phase I data of BGM0504.

The announcement shows that in the 10mg and 20mg dosage groups, with weight-loss effects already observed, no gastrointestinal adverse events occurred; overall adverse reactions were mainly mild and transient, with no serious adverse events.

In terms of pharmacokinetics, BGM0504 is administered once daily. Steady-state blood concentrations can be reached within 2 to 3 weeks, and linear pharmacokinetic characteristics are observed in the 10 to 80mg range, supporting a stable QD dosing regimen.

This means its therapeutic effect release is closer to “steady-state coverage,” rather than repeated fluctuations throughout the day. In chronic-disease management settings, such stability is often more clinically meaningful than short-term peak levels, and it is also more conducive to establishing long-term adherence.

Industrialization capabilities determine the endgame of the oral track

As weight-loss drugs gradually move toward mainstream use, industrialization capabilities are becoming a key variable in determining the competitive landscape.

Oral formulations are inherently closer to chronic-disease medication. They have long usage cycles and high price sensitivity, and costs will directly affect penetration rates and market space. Therefore, future competition will be not only a battle of efficacy, but a comprehensive contest of efficacy and cost.

Based on the available data, BGM0504 has already achieved clear weight-loss effects within the lower dosage range, leaving room for optimization of unit treatment cost. At the same time, Borui Pharmaceutical’s accumulated capabilities in peptide synthesis, process development, and supply-chain systems are expected to further reduce production costs.

Under this context, products that can simultaneously deliver efficacy advantages, controllable costs, and convenient administration are more likely to take a core position in competition in the next stage.

From this perspective, the oral dual-target peptide pathway is moving from technological exploration toward industrialized realization, and BGM0504 is expected to become a key variable in this evolution process.

(This article does not constitute any investment advice. The information disclosure content shall be subject to the company announcements. Investors who act on this information do so at their own risk.)

Massive information, precise insights—right here in the Sina Finance app